AU2010249330B2 - Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response - Google Patents

Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response Download PDF

Info

Publication number
AU2010249330B2
AU2010249330B2 AU2010249330A AU2010249330A AU2010249330B2 AU 2010249330 B2 AU2010249330 B2 AU 2010249330B2 AU 2010249330 A AU2010249330 A AU 2010249330A AU 2010249330 A AU2010249330 A AU 2010249330A AU 2010249330 B2 AU2010249330 B2 AU 2010249330B2
Authority
AU
Australia
Prior art keywords
seq
hsv
vaccine formulation
amino acid
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010249330A
Other languages
English (en)
Other versions
AU2010249330A1 (en
Inventor
Jessica Flechtner
Deborah Long
George R. Siber
Mojca Skoberne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genocea Biosciences Inc
Original Assignee
Genocea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genocea Biosciences Inc filed Critical Genocea Biosciences Inc
Publication of AU2010249330A1 publication Critical patent/AU2010249330A1/en
Application granted granted Critical
Publication of AU2010249330B2 publication Critical patent/AU2010249330B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2010249330A 2009-05-22 2010-05-24 Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response Ceased AU2010249330B2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US18078409P 2009-05-22 2009-05-22
US61/180,784 2009-05-22
US23562809P 2009-08-20 2009-08-20
US61/235,628 2009-08-20
US24058709P 2009-09-08 2009-09-08
US24062609P 2009-09-08 2009-09-08
US61/240,626 2009-09-08
US61/240,587 2009-09-08
US30591810P 2010-02-18 2010-02-18
US61/305,918 2010-02-18
PCT/US2010/035998 WO2010135747A1 (en) 2009-05-22 2010-05-24 Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Publications (2)

Publication Number Publication Date
AU2010249330A1 AU2010249330A1 (en) 2012-01-19
AU2010249330B2 true AU2010249330B2 (en) 2015-11-05

Family

ID=43126545

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010249330A Ceased AU2010249330B2 (en) 2009-05-22 2010-05-24 Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response

Country Status (17)

Country Link
US (3) US8617564B2 (enExample)
EP (3) EP3756684A1 (enExample)
JP (2) JP5771605B2 (enExample)
KR (1) KR101746872B1 (enExample)
CN (2) CN106924728B (enExample)
AU (1) AU2010249330B2 (enExample)
BR (1) BRPI1012811A2 (enExample)
CA (1) CA2797937C (enExample)
ES (1) ES2732815T3 (enExample)
IL (1) IL216508A (enExample)
MX (1) MX2011012347A (enExample)
MY (1) MY159500A (enExample)
NZ (1) NZ597182A (enExample)
RU (1) RU2585961C9 (enExample)
SG (1) SG176207A1 (enExample)
WO (2) WO2010135747A1 (enExample)
ZA (1) ZA201109444B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101746872B1 (ko) 2009-05-22 2017-06-14 제노시아 바이오사이언스, 인크. 단순 포진 바이러스 유형 2에 대한 백신: 면역 반응을 유도하는 조성물 및 방법
JP2013525271A (ja) 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
US9782474B2 (en) 2010-11-24 2017-10-10 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
WO2012139099A2 (en) * 2011-04-08 2012-10-11 Duke University Herpes simplex virus vaccine
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US9624273B2 (en) * 2011-11-23 2017-04-18 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US9555099B2 (en) * 2012-05-16 2017-01-31 Immune Design Corp. Vaccines for HSV-2
US20140093537A1 (en) * 2012-09-30 2014-04-03 Nanobio Corporation Immunogenic compositions comprising nanoemulsion and methods of administering the same
CN103074337B (zh) * 2012-12-04 2014-07-09 昆明寰基生物芯片产业有限公司 一段单纯疱疹病毒dna序列及应用
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
WO2014164699A1 (en) * 2013-03-11 2014-10-09 The Regents Of The University Of California Herpes virus vaccines and treatments
AU2015225499B2 (en) 2014-03-03 2020-05-14 Albert Einstein College Of Medicine, Inc. Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
SMT202100705T1 (it) 2016-02-01 2022-03-21 Simplexia Ab Glicoproteina g troncata del virus dell'herpes sim-plex 2
CA3017487A1 (en) * 2016-04-08 2017-10-12 Krystal Biotech, Inc. Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
KR101962683B1 (ko) * 2016-09-28 2019-03-27 주식회사 에스엘백시젠 Hsv-2 감염 예방 및 치료용 dna 백신
WO2018064232A1 (en) * 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes
US11160860B2 (en) 2017-04-26 2021-11-02 Merck Sharp & Dohme Corp. HSV antigenic peptides and HSV protein vaccines
EP4242223A3 (en) * 2017-08-17 2024-03-13 The Trustees of The University of Pennsylvania Modified mrna vaccines encoding herpes simplex virus glycoproteins and uses thereof
US11213582B2 (en) * 2018-08-08 2022-01-04 The Regents Of The University Of California Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits
PE20211112A1 (es) 2018-09-12 2021-06-22 Affinivax Inc Vacunas neumococicas multivalentes
SG11202109702QA (en) 2019-03-21 2021-10-28 Codiak Biosciences Inc Extracellular vesicles for vaccine delivery
JP2022525924A (ja) 2019-03-21 2022-05-20 コディアック バイオサイエンシーズ， インコーポレイテッド 細胞外小胞コンジュゲート及びその使用
CN109943592B (zh) * 2019-04-29 2020-11-17 华中农业大学 含猪伪狂犬病病毒gD蛋白基因的重组杆状病毒转移载体、重组杆状病毒及制备方法和应用
CN110746497A (zh) * 2019-11-18 2020-02-04 维塔恩(广州)医药有限公司 肺炎衣原体相关抗原短肽及其应用
CN110804088A (zh) * 2019-11-18 2020-02-18 维塔恩(广州)医药有限公司 巨细胞病毒相关抗原短肽及其应用
CN110845583A (zh) * 2019-11-18 2020-02-28 维塔恩(广州)医药有限公司 水痘带状疱疹病毒相关抗原短肽及其应用
CN110724181A (zh) * 2019-11-18 2020-01-24 维塔恩(广州)医药有限公司 单纯疱疹病毒相关抗原短肽及其应用
US11779660B2 (en) 2021-04-02 2023-10-10 Krystal Biotech, Inc. Viral vectors for cancer therapy
WO2023039223A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016779A1 (en) * 1993-12-14 1995-06-22 Smithkline Beecham Biologicals (S.A.) Herpes-symplex-virus type 2 icp4 protein and its use in a vaccine composition
US5851533A (en) * 1983-08-30 1998-12-22 Genentech, Inc. Vaccine based on membrane bound proteins and process for making them
WO2003086308A2 (en) * 2002-04-11 2003-10-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2003099860A2 (en) * 2002-05-24 2003-12-04 Societe D'etude Et De Developpement Des Antigenes Combinatoires - Sedac Therapeutics Immunogenic composition and peptide sequences for prevention and treatment of an hsv condition
WO2004009021A2 (en) * 2002-07-18 2004-01-29 University Of Washington Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
WO2005028496A2 (en) * 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
WO2008030560A2 (en) * 2006-09-08 2008-03-13 The Trustees Of The University Of Pennsyvania Hsv-1 and hsv-2 vaccines and methods of use thereof
WO2008085486A1 (en) * 2006-12-28 2008-07-17 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818694A (en) 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5612041A (en) 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
EP0471778A1 (en) 1989-05-12 1992-02-26 Ciba Corning Diagnostics Corp. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
DE69131200T2 (de) 1990-08-02 1999-12-09 Chiron Corp., Emeryville Herpes simplex virus vp16 impfstoffe
DK31991D0 (da) 1991-02-25 1991-02-25 Carlbiotech Ltd As Peptid og farmaceutisk praeparat indeholdende et saadant peptid
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5679348A (en) 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
JPH08510918A (ja) 1993-06-08 1996-11-19 アボツト・ラボラトリーズ 単純ヘルペスウィルス２型プロテアーゼ
AU7568294A (en) 1993-08-20 1995-03-21 Smithkline Beecham Corporation Hsv-2 ul26 gene, capsid proteins, immunoassays and protease inhibitors
US7094767B2 (en) 1994-07-22 2006-08-22 Merck & Co., Inc. Polynucleotide herpes virus vaccine
US6156319A (en) * 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
US5807557A (en) 1994-07-25 1998-09-15 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1996032962A1 (en) 1995-04-21 1996-10-24 The University Of New Mexico Immunoassay for herpes simplex virus
US5654174A (en) 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
US5876923A (en) 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
CN1324139C (zh) * 1996-10-23 2007-07-04 惠氏 疫苗
KR100564268B1 (ko) 1996-10-23 2006-03-27 와이어쓰 백신
JP2001508649A (ja) 1996-11-04 2001-07-03 スミスクライン・ビーチャム・コーポレイション ２型単純ヘルペスウイルス由来の新規コーディング配列
US6218103B1 (en) * 1997-04-16 2001-04-17 Arch Development Corporation Herpes simplex virus US3 and ICP4 as inhibitors of apoptosis
JP2002503251A (ja) 1997-06-02 2002-01-29 カイロン コーポレイション 単純ヘルペスウイルスｖｐ２２ワクチンおよび使用の方法
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6054131A (en) 1998-01-16 2000-04-25 University Of Maryland Baltimore Vaccine composition for herpes simplex virus and method of using
CA2324289C (en) 1998-03-09 2010-07-13 Smithkline Beecham Biologicals S.A. Combined vaccine compositions
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
DK2272859T3 (en) 1998-08-07 2015-01-19 Univ Washington Immunological herpes simplex virus antigens and methods for their use
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
AU782154C (en) * 1999-06-10 2006-02-09 Boehringer Ingelheim Animal Health USA Inc. DNA vaccines for pets and sport animals
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
JP2003512305A (ja) 1999-09-30 2003-04-02 ユニバーシティ オブ ワシントン 免疫学的に重要な単純疱疹ウイルス抗原
US7196066B1 (en) * 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
KR100773390B1 (ko) * 1999-12-17 2007-11-09 와이어쓰 홀딩스 코포레이션 단순 포진 바이러스 백신 키트
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20030165819A1 (en) 2000-06-29 2003-09-04 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
ATE349533T1 (de) 2000-06-29 2007-01-15 Corixa Corp Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen
US6682892B2 (en) 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
EP1305435B1 (en) 2000-07-27 2007-12-19 The Trustees Of The University Of Pennsylvania Use of herpes simplex virus glycoprotein d to suppress immune responses
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
WO2003034981A2 (en) 2000-11-16 2003-05-01 University Of Maryland, Baltimore Prevention of recurrent viral disease
US6867000B2 (en) 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
US7314624B2 (en) 2001-06-05 2008-01-01 The Regents Of The University Of Michigan Nanoemulsion vaccines
EP2191845A1 (en) 2001-07-31 2010-06-02 University of Washington Immunology significant herpes simplex virus antigens and methods for using same
WO2003020108A2 (en) 2001-09-04 2003-03-13 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20080299140A1 (en) 2002-05-24 2008-12-04 The Regents Of The University Of California, Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition
US7267940B2 (en) 2003-03-04 2007-09-11 Bio-Rad Laboratories, Inc. HSV-2 type-specific immunoassays using glycoprotein G2 peptides
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
WO2007097820A2 (en) 2005-11-18 2007-08-30 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
US8501194B2 (en) 2006-03-10 2013-08-06 The Regents Of The University Of California Vaccine for viruses that cause persistent or latent infections
CA2658484A1 (en) 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
WO2008027394A2 (en) 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
CA2668100C (en) 2006-11-01 2014-12-23 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US7785605B2 (en) 2007-07-05 2010-08-31 University Of Kansas Herpes simplex virus mutant ICP0 protein
US20130273088A1 (en) 2007-07-06 2013-10-17 Anthony Lawrence Cunningham Epitopes of herpes simplex virus
EP2293814A4 (en) * 2008-05-23 2013-02-13 Univ Michigan NANOEMULSION AGENTS
SE532551C2 (sv) 2008-06-30 2010-02-16 Senseair Ab Ett för spektralanalys anpassat arrangemang
EP2300828B1 (en) 2008-07-01 2018-09-05 Genocea Biosciences Inc. Antigen screening system
WO2010078027A1 (en) 2008-12-17 2010-07-08 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
JP2012519724A (ja) 2009-03-09 2012-08-30 ヘンルイ ウイルリアム シグナルペプチドを担体として有する細菌毒素とのハプテン‐担体抱合体及び免疫原性組成物としてのその使用
KR101746872B1 (ko) 2009-05-22 2017-06-14 제노시아 바이오사이언스, 인크. 단순 포진 바이러스 유형 2에 대한 백신: 면역 반응을 유도하는 조성물 및 방법
WO2011106607A2 (en) 2010-02-26 2011-09-01 Juvaris Biotherapeutics, Inc. Subunit vaccines for herpes viruses and methods of use
ES2651005T3 (es) 2010-03-09 2018-01-23 Biomedical Research Models, Inc. Una nueva estrategia de vacunación mucosa para el virus del herpes simple tipo-2
AU2011316924A1 (en) 2010-10-20 2013-05-02 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
US9782474B2 (en) 2010-11-24 2017-10-10 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US9624273B2 (en) 2011-11-23 2017-04-18 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851533A (en) * 1983-08-30 1998-12-22 Genentech, Inc. Vaccine based on membrane bound proteins and process for making them
WO1995016779A1 (en) * 1993-12-14 1995-06-22 Smithkline Beecham Biologicals (S.A.) Herpes-symplex-virus type 2 icp4 protein and its use in a vaccine composition
WO2003086308A2 (en) * 2002-04-11 2003-10-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2003099860A2 (en) * 2002-05-24 2003-12-04 Societe D'etude Et De Developpement Des Antigenes Combinatoires - Sedac Therapeutics Immunogenic composition and peptide sequences for prevention and treatment of an hsv condition
WO2004009021A2 (en) * 2002-07-18 2004-01-29 University Of Washington Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
WO2005028496A2 (en) * 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
WO2008030560A2 (en) * 2006-09-08 2008-03-13 The Trustees Of The University Of Pennsyvania Hsv-1 and hsv-2 vaccines and methods of use thereof
WO2008085486A1 (en) * 2006-12-28 2008-07-17 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ASHLEY R., et al, Journal of Virology, 1985, vol 56, pages 475-481 *
LANGENBERG A. G. M., et al, Annals of Internal Medicine, 1995, vol 122, pages 889-898 *
MESEDA C. A., et al, The Journal of Infectious diseases, 2002, vol.186, pages 1065-1073 *
STRASSER J. E., et al, The Journal of Infectious Diseases, 2000, vol 182, pages 1304-1310 *

Also Published As

Publication number Publication date
JP2015178529A (ja) 2015-10-08
US20180369365A1 (en) 2018-12-27
RU2585961C2 (ru) 2016-06-10
MX2011012347A (es) 2012-02-21
CN106924728A (zh) 2017-07-07
ZA201109444B (en) 2016-09-28
US20140227307A1 (en) 2014-08-14
WO2010135747A1 (en) 2010-11-25
CN102458463B (zh) 2017-01-18
RU2011147153A (ru) 2013-06-27
KR101746872B1 (ko) 2017-06-14
MY159500A (en) 2017-01-13
WO2010135749A1 (en) 2010-11-25
EP3756684A1 (en) 2020-12-30
JP2012527486A (ja) 2012-11-08
CN106924728B (zh) 2021-02-05
JP6096839B2 (ja) 2017-03-15
US20100330112A1 (en) 2010-12-30
WO2010135749A9 (en) 2011-07-21
US9895436B2 (en) 2018-02-20
EP2432504B1 (en) 2019-05-01
IL216508A (en) 2016-08-31
EP2432504A1 (en) 2012-03-28
CA2797937A1 (en) 2010-11-25
US8617564B2 (en) 2013-12-31
EP3590533A1 (en) 2020-01-08
KR20120087805A (ko) 2012-08-07
ES2732815T3 (es) 2019-11-26
AU2010249330A1 (en) 2012-01-19
CA2797937C (en) 2020-01-14
IL216508A0 (en) 2012-02-29
JP5771605B2 (ja) 2015-09-02
BRPI1012811A2 (pt) 2016-03-29
NZ597182A (en) 2014-07-25
EP2432504A4 (en) 2013-07-31
US10653771B2 (en) 2020-05-19
RU2585961C9 (ru) 2016-12-27
CN102458463A (zh) 2012-05-16
SG176207A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
US10653771B2 (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US10350288B2 (en) Methods and compositions for treating herpes
US9782474B2 (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US9624273B2 (en) Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ: LONG, DEBORAH; FLECHTNER, JESSICA; SKOBERNE, MOJCA AND SIBER, GEORGE R.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired